Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment
Baseline cfDNA CNA profiling in chemotherapy-naïve mCRPC reveals recurrent chromosomal imbalances-particularly 8p loss and 8q gain-that may represent intrinsic, stable features of advanced disease. These findings highlight the exploratory potential of cfDNA-based genomics in rare PSMA-RPT cohorts.
Authors
- Frank Bruchertseifer (ORCID: https://orcid.org/0000-0003-2125-4483)
- V. Benes
- Mariam Amghar
- Hilal Ozgur
- Alfred Morgenstern
- Clemens Kratochwil
- Martina Benešová-Schäfer
Institutions
- German Cancer Research Center (DE)
- European Commission (BE)
- European Molecular Biology Laboratory (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fonc.2026.1741080
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsches Krebsforschungszentrum
- Ministry of Science, Technology and Space